Peripheral extracorporeal membrane oxygenation (ECMO) in patients with posttransplant cardiac graft failure.

INTRODUCTION: We sought to report the usefulness of extracorporeal membrane oxygenation (ECMO) in heart transplant patients. PATIENTS: Between March 2002 and August 2004, 14 heart transplant patients (11 men and three women, 36 +/- 15 years old, range = 12 to 50) with primary graft failure underwent peripheral ECMO implantation. Three patients had pulmonary hypertension and three had been transplanted with hearts from marginal donors. At the time of implantation, all were in severe cardiogenic shock despite maximal inotropic support. In six patients, the ECMO was implanted in the operating room since cardiopulmonary bypass could not be weaned. In the eight remaining patients, ECMO was implanted in the intensive care unit, during the first 48 hours in seven cases. In one patient, implantation was performed during external resuscitation. In all cases, femoral vessels were canulated using the Seldinger technique after anterior wall exposure. Distal arterial perfusion of the lower limb was systematically used. RESULTS: Pump outflow was high enough in all the cases (mean: 2.6 +/- 0.2 L/min/m(2)). Three patients died on circulatory support. One patient was implanted with a total artificial heart after a few hours and another one underwent unsuccessful emergent retransplantation. Nine patients were weaned from ECMO after a mean duration of 5 +/- 2.5 days. Among them, one died of infection at 10 days after weaning and seven others were discharged to rehabilitation centers. CONCLUSION: Fast operating room or bedside implantation of a peripheral ECMO allows the physician to stabilize the hemodynamic status of patients with cardiac graft failure, potentially leading toward myocardial recovery.

[Totally implantable completely electric artificial heart: "AbioCor"]. / Coeur artificiel total électrique totalement implantable: "AbioCor".

The fully implantable complete electric artificial heart "AbioCor" is the ultimate stage in the 3rd generation assistance systems. It has been authorized for clinical use since last year by the Food and Drug Administration (F.D.A.). It is an electrohydraulic heart developed by Abiomed. It consists of implanted internal components: the cardiac pump, an internal lithium battery, a controller and an internal coil allowing electrical energy transfer across the skin, and external components: an external coil and external batteries. The one-piece heart includes two ventricular chambers: right and left. All of the surfaces in contact with blood as well as the four three-leaved valves are made of polyurethane. An electro-hydraulic energy converter powers the ventricles. A stroke volume of 60 to 65 ml allows an output of between 4 and 10 L.min-1. Between 2 July 2002 and 4 November 2002, seven males, aged between 51 and 70 years, underwent implantation. They were suffering from ischaemic cardiopathy (6 cases) or idiopathic dilated cardiopathy (1 case). Among the late complications, 3 severe embolic cerebrovascular accidents occurred. Four late deaths occurred.

[Fulminating myocarditis: myocardial recovery after circulatory assistance]. / Myocardite fulminante: récupération myocardique après assistance circulatoire.

The clinical expression of acute myocarditis is variable from paucisymptomatic to fulminating forms which are usually lethal within days. The latter presentation takes the form of very acute cardiac failure. During this phase, the severity of myocardial dysfunction may be such that death ensues. However, if the patient survives, paradoxically, these forms have a better long-term prognosis with complete recovery of myocardial function being possible after the acute phase. The authors report a typical case of fulminating myocarditis with electromechanical dissociation, which recovered completely after a period of circulatory assistance. This case illustrates the rapidity of deterioration of the haemodynamic status and the importance of organ dysfunction despite early management. In a review of the literature, the authors found about 150 reported cases of acute myocarditis treated with circulatory assistance. In the best series, about half the patients were weaned off the circulatory assistance without having to undergo cardiac transplantation. However, the potential recovery of myocardial function is difficult to predict.